Pfizer Inc. (NYSE:PFE) Shares Sold by Childress Capital Advisors LLC

Childress Capital Advisors LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 2.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,951 shares of the biopharmaceutical company’s stock after selling 982 shares during the period. Childress Capital Advisors LLC’s holdings in Pfizer were worth $1,301,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in PFE. Olistico Wealth LLC bought a new stake in Pfizer in the second quarter valued at $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the 2nd quarter valued at about $29,000. Quarry LP acquired a new position in Pfizer during the 2nd quarter valued at about $31,000. Financial Connections Group Inc. bought a new position in Pfizer in the 2nd quarter worth about $34,000. Finally, ESL Trust Services LLC acquired a new stake in shares of Pfizer in the first quarter valued at approximately $37,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 1.4 %

Shares of NYSE PFE opened at $28.47 on Wednesday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company has a market cap of $161.33 billion, a price-to-earnings ratio of -61.89, a P/E/G ratio of 0.99 and a beta of 0.67. The business has a fifty day simple moving average of $29.07 and a 200-day simple moving average of $28.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.90%. Pfizer’s dividend payout ratio (DPR) is presently -365.21%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Barclays raised their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.